Risk Factors Update Summary
- Collaboration with Gilead poses risks including conflicts, funding uncertainties, and dependence on Gilead's decisions.
- Insufficient resources for all nonclinical and clinical studies internally, especially due to geopolitical disruptions.
- Failure to establish collaborations may limit product development, impacting business, operations, and financials.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1426800&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.